Citigroup
IMDX

Citigroup’s Insight Molecular Diagnostics IMDX Stock Holding History

Citigroup’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.67K Buy
815
+814
+81,400% +$4.73K ﹤0.01% 5383
2025
Q4 		$8 Buy
+1
New +$6 ﹤0.01% 5827
2023
Q2 		– Sell
-7
Closed -$49 – 5683
2023
Q1 		$49 Sell
7
-45
-87% -$334 ﹤0.01% 5327
2022
Q4 		$309 Buy
52
+8
+18% +$88 ﹤0.01% 5560
2022
Q3 		$1K Sell
44
-132
-75% -$2.29K ﹤0.01% 5660
2022
Q2 		$3K Sell
176
-38
-18% -$864 ﹤0.01% 5787
2022
Q1 		$6K Sell
214
-700
-77% -$22.4K ﹤0.01% 5762
2021
Q4 		$39K Buy
914
+571
+166% +$32.8K ﹤0.01% 5187
2021
Q3 		$24K Buy
343
+149
+77% +$13.7K ﹤0.01% 5155
2021
Q2 		$22K Sell
194
-42
-18% -$4.1K ﹤0.01% 5250
2021
Q1 		$24K Sell
236
-353
-60% -$33.5K ﹤0.01% 5145
2020
Q4 		$28K Buy
589
+438
+290% +$16.1K ﹤0.01% 6441
2020
Q3 		$4K Sell
151
-140
-48% -$4.01K ﹤0.01% 7134
2020
Q2 		$11K Sell
291
-8
-3% -$413 ﹤0.01% 7008
2020
Q1 		$15K Buy
299
+81
+37% +$3.97K ﹤0.01% 6862
2019
Q4 		$10K Buy
218
+165
+311% +$5.95K ﹤0.01% 7205
2019
Q3 		$2K Sell
53
-266
-83% -$10.5K ﹤0.01% 7546
2019
Q2 		$16K Sell
319
-719
-69% -$59.8K ﹤0.01% 7162
2019
Q1 		$82K Buy
+1,038
New +$66.9K ﹤0.01% 5934
2018
Q2 		– Sell
-2
Closed – – 7690
2018
Q1 		$0 Sell
2
-1
-33% -$66 ﹤0.01% 7630
2017
Q4 		$0 Buy
+3
New +$338 ﹤0.01% 7622
2017
Q3 		– Sell
-494
Closed -$51K – 7383
2017
Q2 		$51K Buy
+494
New +$56.2K ﹤0.01% 5778
2016
Q4 		– Sell
-2
Closed – – 7281
2016
Q3 		$0 Buy
+2
New +$161 ﹤0.01% 7146
2016
Q2 		– Sell
-138
Closed -$13K – 7312
2016
Q1 		$13K Buy
+138
New +$12.2K ﹤0.01% 6728

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citigroup's IMDX Position: Q1 2026 in Review

Citigroup increased its Insight Molecular Diagnostics (IMDX) stake by 81,400% in Q1 2026, buying an estimated $4.73K and bringing the position to 815 shares worth $2.67K. The position accounts for ﹤0.01% of the portfolio, ranked #5383.

Citigroup first reported a position in IMDX in Q1 2016 and has held it in 24 quarters since. The position peaked at $82K in Q1 2019. 41 funds tracked by Wall St. Rank hold IMDX as of Q1 2026.

  • Citigroup held 815 shares of Insight Molecular Diagnostics worth $2.67K as of Q1 2026.
  • Citigroup bought 814 Insight Molecular Diagnostics shares in Q1 2026, an estimated $4.73K.
  • Insight Molecular Diagnostics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5383 holding.
  • Citigroup first reported a position in Insight Molecular Diagnostics in Q1 2016 and has held it in 24 quarters since.
  • Citigroup's Insight Molecular Diagnostics position peaked at $82K in Q1 2019.
  • 41 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.